Le Lézard
Classified in: Health, Business
Subjects: CON, CXP

SRX HEALTH SOLUTIONS INC. CELEBRATES ADDITION OF NEW PHARMACY IN COQUITLAM, BC.


TORONTO, Oct. 31, 2023 /CNW/ - SRx Health Solutions Inc.  ("SRx" or the "Company") Expands Its Reach and Services with Mediglen Pharmacy & Compounding ("Mediglen") Partnership. 

SRx, a leading healthcare provider, is pleased to announce that Mediglen Pharmacy & Compounding ("Mediglen"), a well-respected pharmacy centrally located in the city of Coquitlam, British Columbia, have joined the Companies network. This partnership highlights SRx's commitment to servicing communities throughout Canada.   

"The partnership marks another instrumental milestone towards accomplishing our goal to make specialty pharmacy services and integrated care more accessible," stated Adesh Vora, the Company's Chief Executive Officer. "We welcome Mediglen's team members to our Company and are fully committed to making this transition as seamless as possible for employees and patients alike. We are proud of what we have achieved to date and continue to pursue our goal of making healthcare simpler for Canadians."

Since its inception,?SRx's focus has been to provide exceptional care and support to its valued patients. The addition of Mediglen Pharmacy & Compounding represents a significant footprint expansion and is expected to help the company provide Canadians residing in Coquitlam and the surrounding areas with greater access to SRx's integrated, innovative, and specialized care services. As stated by Arash Pourzare, PharmD, RPh, CDE, Owner/Manager of Mediglen, "Joining SRx means bringing a revolutionary patient-focused approach to our beloved Coquitlam community. We are eager to witness this new chapter in healthcare excellence."

About SRx Health Solutions Inc. 

SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country.?SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians.? 

For more information on SRx Health Solutions Inc., please visit www.srxhealth.ca

Cautionary Statement Regarding Forward-Looking Information

This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws, which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to the Company's plans to integrate newly acquired pharmacies into its specialty care infrastructure, and the Company's eagerness to support more patients, among others.

These forward-looking statements reflect management's current beliefs with respect to future events and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and the Company has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

SOURCE SRx Health Solutions


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: